Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper

European Respiratory Journal

Volumn 23, Issue 6, 2004, Pages 932-946

  Celli, B R ^a   MacNee, W ^a   Agusti, A ^b   Anzueto, A ^b   Berg, B ^b   Buist, A S ^b   Calverley, P M A ^b   Chavannes, N ^b   Dillard, T ^b   Fahy, B ^b   Fein, A ^b   Heffner, J ^b   Lareau, S ^b   Meek, P ^b   Martinez, F ^b   McNicholas, W ^b   Muris, J ^b   Austegard, E ^b   Pauwels, R ^b   Rennard, S ^b   Rossi, A ^b   Siafakas, N ^b   Tiep, B ^b   Vestbo, J ^b   Wouters, E ^b   ZuWallack, R ^b   more..

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLARITHROMYCIN; DIRITHROMYCIN; DOXYCYCLINE; GATIFLOXACIN; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NICOTINE; OXYGEN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; FUTUROLOGY; HEALTH PRACTITIONER; HUMAN; INFORMATION PROCESSING; INTERNET; LUNG SURGERY; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; MEDICAL RECORD; MEDICAL SOCIETY; OXYGEN THERAPY; PRIORITY JOURNAL; RESPIRATORY ACIDOSIS; REVIEW; SCORING SYSTEM; SIDE EFFECT; SPIROMETRY; STANDARD; TOBACCO DEPENDENCE;

EID: 1842552109     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00014304     Document Type: Review

References (105)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S121.
2. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
4. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease and health related quality of life. Ann Int Med 1997; 127: 1072-1079.
5. Friedman M, Serby C, Menjoge S, Wilson J, Hilleman D, Witek T. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635-641.
6. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
7. Dewan N, Rafique S, Kanwar B, et al. Acute exacerbation of COPD. Factors associated with poor treatment outcome. Chest 2000; 117: 662-671.
8. Anthonisen NR, Wright EC, Hodgkin JE, the IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14-20.
9. Celli B, Halbert R, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-273.
10. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-1797.
11. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861.
12. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.
13. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance United States, 1971-2000. MMWR 2002; 51: 1-16.
14. Prescott E. Tobacco-related diseases: the role of gender. Dan Med Bull 2000; 47: 115-131.
15. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-994.
16. Fletcher CM, Tinker CM, Peto R, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford, Oxford University Press, 1976.
17. Gold DR, Wang X, Wipyj D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335: 931-937.
18. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
19. Rennard SI. Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S12-S16.
20. Peinado VI, Barbera JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-1611.
21. Rodriguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. Eur Respir Mono 1998; 3: 107-126.
22. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
23. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357.
24. Matsuba K, Wright JL, Wiggs BR, Pare PD, Hogg JC. The changes in airways structure associated with reduced forced expiratory volume in one second. Eur Respir J 1989; 2: 834-839.
25. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-777.
26. Fiore MC, Bailey WC, Cohen SJ. Smoking cessation. Guideline technical report no. 18. Publication No. AHCPR 97-Noo4. Rockville, MD, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, October 1997.
27. Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000; 45: 1200-1262.
28. Office of the Surgeon General. Tobacco Cessation Guideline www.surgeongeneral.gov/tobacco/default.htm. Data last updated: continuous.
29. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
30. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549.
31. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-975.
32. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-784.
33. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
34. Combivent trialists. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105: 1411-1419.
35. Zuwallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.
36. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
37. Vicken W, Van Noord JA, Greefhorst AP, et al., on behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 year treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
38. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
39. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. New Engl J Med 1999; 340: 1948-1953.
40. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New Engl J Med 2000; 343: 1902-1909.
41. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999; 353: 1819-1823.
42. Jarad NA, Wedzicha JA, Burge PS, Calverley PMA. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999: 93: 161-168.
43. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
44. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of COPD. Eur Respir J 2003; 21: 74-81.
45. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
46. Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-685.
47. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980; 93: 391-398.
48. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-498.
49. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198.
50. Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinksi P, Palasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 1998; 113: 65-70.
51. Tiep BL, Barnett J, Schiffman G, Sanchez O, Carter R. Maintaining oxygenation via demand oxygen delivery during rest and exercise. Respir Care 2002; 47: 887-892.
52. Pulmonary rehabilitation: official statement of the American Thoracic Society. Am J Respir Crit Care Med 1999; 159: 1666-1682.
53. Goldstein RS, Gort EH, Stubbing D, et al. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394-1397.
54. Reardon J, Awad E, Normandin E, Vale F, Clark B, ZuWallack RL. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 1994; 105: 1046-1052.
55. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122: 823-832.
56. Wijkstra PJ, van der Mark TW, Kraan J, van Altena R, Koeter GH, Postma DS. Effects of home rehabilitation on physical performance in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1996; 9: 104-110.
57. Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter GH. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months. Chest 1996; 109: 366-372.
58. . Schols AMWJ, Soeters PB, Dingemans AMC, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
59. Schols AM, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: A randomised controlled trial. Am J Respir Crit Care Med 1995; 152: 1248-1274.
60. Creutzberg EL, Wouters EFM, Mostert R, et al. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition 2003; 19: 120-127.
61. Arozullah AM, Khuri SF, Henderson WG, Daley J. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major non-cardiac surgery. Ann Intern Med 2001; 135: 847-857.
62. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999; 340: 937-944.
63. Trayner E Jr, Celli BR. Postoperative pulmonary complications. Med Clin North Am 2001; 85: 1129-1139.
64. Weisman IM. Cardiopulmonary exercise testing in the preoperative assessment for lung resection surgery. Semin Thorac Cardiovasc Surg 2001; 13: 116-125.
65. Martinez FJ, Iannettoni M, Paine III R. Medical evaluation and management of the lung cancer patient prior to surgery, radiation or chemotherapy. In: Pass H, Mitchell J, Johnson D, Turrisi A, eds. Lung cancer: principles and practice. Philadelphia, PA, Lippincott Williams & Williams, 2000; pp. 649-681.
66. Bolliger CT, Jordan P, Soler M, et al. Pulmonary function and exercise capacity after lung resection. Eur Respir J 1996; 9: 415-421.
67. Bolliger CT, Perruchoud AP. Functional evaluation of the lung resection candidate. Eur Respir J 1998; 11: 198-212.
68. Martinez FJ. Surgical therapy for chronic obstructive pulmonary disease: conventional bullectomy and lung volume reduction surgery in the absence of giant bullae. Semin Respir Crit Care Med 1999; 20: 351-364.
69. Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Chest 1996; 109: 540-548.
70. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073.
71. American Thoracic Society. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med 1998; 158: 335-339.
72. Hudgel DW, Martin RJ, Capehart M, Johnson B, Hill P. Contribution of hypoventilation to sleep oxygen desaturation in chronic obstructive pulmonary disease. J Appl Physiol 1983; 55: 669-677.
73. Mulloy E, McNicholas WT. Ventilation and gas exchange during sleep and exercise in patients with severe COPD. Chest 1996; 109: 387-394.
74. Klink M, Quan S. Prevalence of reported sleep disturbances in a general population and their relationship to obstructive airways diseases. Chest 1987; 91: 540-546.
75. Sanders MH, Newman AB, Haggerty CL, et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003; 167: 7-14.
76. 2 above 60 mm Hg. Am Rev Respir Dis 1992; 145: 1070-1076.
77. Dillard TA, Berg BW, Rajagopal KR, Dooley JW, Mehm WJ. Hypoxemia during air travel in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989; 111: 362-367.
78. Christensen CC, Ryg M, Refvem OK, et al. Development of severe hypoxaemia in chronic obstructive pulmonary disease patients at 2438 m (8000 ft) altitude. Eur Respir J 2000; 15: 635-639.
79. Gong H, Tashkin DP, Lee EY, Simmons MS. Hypoxia-altitude simulation test. Am Rev Respir Dis 1984; 130: 980-986.
80. AMA Commission on Emergency Medical Services. Medical aspects of transportation aboard commercial aircraft. JAMA 1982; 247: 1007-1011.
81. Berg BW, Dillard TA, Rajagopal KR, Mehm WJ. Oxygen supplementation during air travel in patients with chronic obstructive pulmonary disease. Chest 1992; 101: 638-641.
82. Emerman CL, Cydulka RAK. Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1993; 22: 680-684.
83. O'Brien C, Guest PF. Physiological and radiological characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 631-632.
84. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92: 753-758.
85. Niewhoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947.
86. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 345: 456-460.
87. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-412.
88. Aaron S, Vandenheeur K, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-2625.
89. Aubier M, Murciano D, Milie-Emili M, et al. Effects of the administration of oxygen therapy on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980; 122: 747-754.
90. Dumont CP, Tiep BL. Using a reservoir nasal cannula in acute care. Critical Care Nurse 2002; 22: 41-46.
91. Górecka D, Gorzelak K, Śliwiński P, Tobiasz M, Zieliński J. Effect of long term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674-679.
92. O'Donohue WJ. Effect of arterial oxygen therapy on increasing arterial oxygen tension in hypoxemia patients with stable chronic obstructive pulmonary disease while breathing ambient air. Chest 1991; 100: 968-972.
93. Oba Y, Salzman GA, Willsie SK. Re-evaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease. Respir Care 2000; 45: 401-406.
94. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001; 163: 283-291.
95. BTS Guideline. Non invasive ventilation in acute respiratory failure. British Thoracic Society Standards of Care Committee. Thorax 2002; 57: 192-211.
96. Mehta S, Hill NS. Non invasive ventilation. State of the Art. Am J Respir Crit Care Med 2001; 163: 540-577.
97. Lightowler JV, Wedzicha JA, Elliot M, Ram SF. Non invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003; 326: 185-189.
98. Rossi A, Appendini L, Roca J. Physiological aspects of noninvasive positive pressure ventilation. Eur Respir Mon 2001; 16: 1-10.
99. Diaz O, Iglesia R, Ferrer M, et al. Effects of non invasive ventilation on pulmonary gas exchange and hemodynamics during acute hypercapnic exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1840-1845.
100. Conti G, Antonelli M, Navalesi P, et al. Noninvaisve vs conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med 2002; 28: 1701-1707.
101. Plant PK, Owen JL, Elliott MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. Thorax 2001; 56: 708-712.
102. Heffner JE, Fahy B, Hilling L, Barbieri C. Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055-1059.
103. Emanuel EJ, Fairclough DL, Slutsman J, Alpert H, Baldwin D, Emanuel LL. Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients. N Engl J Med 1999; 341: 956-963.
104. Christakis NA, Escarce JJ. Survival of Medicare patients after enrollment in hospice programs. N Engl J Med 1996; 335: 172-178.
105. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med 1996; 124: 832-837.